ES2722436T3 - Acidos hialurónicos sulfatados como agentes antivirales - Google Patents
Acidos hialurónicos sulfatados como agentes antivirales Download PDFInfo
- Publication number
- ES2722436T3 ES2722436T3 ES16178622T ES16178622T ES2722436T3 ES 2722436 T3 ES2722436 T3 ES 2722436T3 ES 16178622 T ES16178622 T ES 16178622T ES 16178622 T ES16178622 T ES 16178622T ES 2722436 T3 ES2722436 T3 ES 2722436T3
- Authority
- ES
- Spain
- Prior art keywords
- hyaluronic acid
- sulfated hyaluronic
- antiviral agents
- sulfation
- hyaluronic acids
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 229920002674 hyaluronan Polymers 0.000 title abstract 4
- 239000003443 antiviral agent Substances 0.000 title 1
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical class CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 abstract 7
- 229960003160 hyaluronic acid Drugs 0.000 abstract 3
- 208000009889 Herpes Simplex Diseases 0.000 abstract 2
- 230000019635 sulfation Effects 0.000 abstract 2
- 238000005670 sulfation reaction Methods 0.000 abstract 2
- 241000701022 Cytomegalovirus Species 0.000 abstract 1
- 241000700588 Human alphaherpesvirus 1 Species 0.000 abstract 1
- 241000701074 Human alphaherpesvirus 2 Species 0.000 abstract 1
- 150000002016 disaccharides Chemical class 0.000 abstract 1
- 150000004676 glycans Chemical class 0.000 abstract 1
- 229920001282 polysaccharide Polymers 0.000 abstract 1
- 239000005017 polysaccharide Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 208000003265 stomatitis Diseases 0.000 abstract 1
- QAOWNCQODCNURD-UHFFFAOYSA-L sulfate group Chemical group S(=O)(=O)([O-])[O-] QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 abstract 1
- 208000005925 vesicular stomatitis Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Physical Education & Sports Medicine (AREA)
- Communicable Diseases (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Diabetes (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Heart & Thoracic Surgery (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Reproductive Health (AREA)
- Pain & Pain Management (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Biotechnology (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Emergency Medicine (AREA)
Abstract
Ácido hialurónico sulfatado para uso en la prevención y/o tratamiento del herpes simple labialis HSV-1, herpes simplex genitalis HSV-2, virus VSV de la estomatitis vesicular, citomegalovirus del CMV, en donde dicho ácido hialurónico sulfatado (HA) tiene un grado de sulfatación, destinado como el número de grupos sulfato por unidad de disacárido, igual a 1 o 3, estando dicho ácido hialurónico sulfatado (HA) preparado a partir de un HA que tiene un peso molecular que varía de 150,000 a 250,000 Da, involucrando la sulfatación solamente a los hidroxilos de alcohol presentes en la cadena de polisacárido (HA).
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ITPD2009A000135A IT1397247B1 (it) | 2009-05-14 | 2009-05-14 | Nuovi agenti regolatori dell'attivita' citochinica |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2722436T3 true ES2722436T3 (es) | 2019-08-12 |
Family
ID=41268269
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES16178622T Active ES2722436T3 (es) | 2009-05-14 | 2010-05-11 | Acidos hialurónicos sulfatados como agentes antivirales |
| ES10721125.2T Active ES2602498T3 (es) | 2009-05-14 | 2010-05-11 | Ácidos hialurónicos sulfatados como agentes reguladores de la actividad de citoquinas |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES10721125.2T Active ES2602498T3 (es) | 2009-05-14 | 2010-05-11 | Ácidos hialurónicos sulfatados como agentes reguladores de la actividad de citoquinas |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US9808482B2 (es) |
| EP (2) | EP2429533B1 (es) |
| CN (2) | CN102421443B (es) |
| CA (2) | CA2967567C (es) |
| ES (2) | ES2722436T3 (es) |
| HR (1) | HRP20161575T8 (es) |
| HU (1) | HUE031174T2 (es) |
| IT (1) | IT1397247B1 (es) |
| LT (1) | LT2429533T (es) |
| PL (1) | PL2429533T3 (es) |
| PT (1) | PT2429533T (es) |
| RU (1) | RU2552337C2 (es) |
| SI (1) | SI2429533T1 (es) |
| SM (2) | SMT201900288T1 (es) |
| WO (1) | WO2010130466A1 (es) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5758797B2 (ja) | 2008-04-04 | 2015-08-05 | ユニバーシティ・オブ・ユタ・リサーチ・ファウンデイション | アルキル化半合成グリコサミノグリカンエーテルならびにその製造および使用方法 |
| US8343942B2 (en) * | 2008-04-04 | 2013-01-01 | University Of Utah Research Foundation | Methods for treating interstitial cystitis |
| IT1397246B1 (it) * | 2009-05-14 | 2013-01-04 | Fidia Farmaceutici | Nuovi medicamenti ad uso topico a base di acido ialuronico solfatato come agente attivante o inibente l'attivita' citochinica |
| US20130209531A1 (en) | 2010-06-08 | 2013-08-15 | University Of Utah Research Foundation | Applications of partially and fully sulfated hyaluronan |
| CA2830933A1 (en) | 2011-03-23 | 2012-09-27 | University Of Utah Research Foundation | Methods for treating or preventing urological inflammation |
| GB201219696D0 (en) * | 2012-11-01 | 2012-12-12 | Univ Liverpool | Agents for the prevention and/or treatment of central nervous system damamge |
| WO2018053111A1 (en) | 2016-09-15 | 2018-03-22 | University Of Utah Research Foundation | In situ gelling compositions for the treatment or prevention of inflammation and tissue damage |
| CN111228653A (zh) | 2018-11-13 | 2020-06-05 | 格莱科米拉治疗公司 | 用电离辐射加强癌症治疗的方法 |
| CN109529021B (zh) * | 2019-01-25 | 2022-11-15 | 山东省分析测试中心 | 一种白细胞介素2抑制破骨细胞生成和功能的新用途 |
| IT201900003887A1 (it) | 2019-03-18 | 2020-09-18 | Fidia Farm Spa | Sistemi di stabilizzazione e di rilascio controllato di farmaci instabili alla sterilizzazione |
| WO2021133000A1 (ko) * | 2019-12-23 | 2021-07-01 | 주식회사 엘지화학 | 항염 또는 항혈관신생용 약제학적 조성물 |
| JP2023517239A (ja) | 2020-03-12 | 2023-04-24 | デイヴィッド カリス－ヒル、シドニー | コロナウイルス感染症および関連するサイトカイン毒性の治療 |
| IT202000032243A1 (it) | 2020-12-23 | 2022-06-23 | Fidia Farm Spa | Nuovi agenti antivirali |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0240098A3 (en) * | 1986-04-04 | 1989-05-10 | Kabushiki Kaisha Ueno Seiyaku Oyo Kenkyujo | Oligo and polysaccharides for the treatment of diseases caused by retroviruses |
| IT1217458B (it) * | 1988-05-02 | 1990-03-22 | Crinos Ind Farmacoriologica S | Sulfoamino derivati di condroitin solfati,del dermatan solfato e dell' acido ialuronico e loro proprieta' farmacologiche |
| CA1340994C (en) * | 1989-09-21 | 2000-05-16 | Rudolf Edgar Dr. Falk | Treatment of conditions and disease |
| DE4021066A1 (de) * | 1990-07-03 | 1992-01-09 | Hoechst Ag | Langzeitprophylaxe gegen erkrankungen, die durch viren oder durch unkonventionelle viren verursacht werden |
| ITPD940054A1 (it) * | 1994-03-23 | 1995-09-23 | Fidia Advanced Biopolymers Srl | Polisaccaridi solfatati |
| DE69621528T2 (de) * | 1995-02-07 | 2003-01-16 | Shiseido Co. Ltd., Tokio/Tokyo | Anti-inflamatorische agenzien |
| JPH10195107A (ja) * | 1997-01-10 | 1998-07-28 | Shiseido Co Ltd | オリゴ硫酸化ヒアルロン酸 |
| ATE229038T1 (de) | 1997-04-04 | 2002-12-15 | Fidia Advanced Biopolymers Srl | N-sulfatierte hyaluronsäureverbindungen, ihre derivate und verfahren zu ihrer herstellung |
| US5981509A (en) * | 1997-05-20 | 1999-11-09 | Shiseido Company, Ltd. | Preparation for prophylaxis or treatment of renal diseases containing sulfated polysaccharide |
| JPH11147901A (ja) * | 1997-11-19 | 1999-06-02 | Maruho Co Ltd | カリクレイン−キニン系阻害剤 |
| JPH11269077A (ja) * | 1998-03-19 | 1999-10-05 | Maruho Co Ltd | ホスホリパーゼａ２阻害用医薬組成物 |
| DE19813234A1 (de) * | 1998-03-26 | 1999-09-30 | Knoell Hans Forschung Ev | Verfahren zur Herstellung hochsulfatierter Hyaluronsäuren |
| JP2000178196A (ja) | 1998-12-11 | 2000-06-27 | Seikagaku Kogyo Co Ltd | 新規ヒアルロニダーゼ阻害剤及び外用剤 |
| JP2001163789A (ja) * | 1999-12-13 | 2001-06-19 | Maruho Co Ltd | マトリックスメタロプロテアーゼ阻害用医薬組成物 |
| GB0003048D0 (en) * | 2000-02-11 | 2000-03-29 | Dealler Stephen F | The therapeutic use of polysulphonated polyglycosides or other polyanionic compounds in autism |
| US7431920B2 (en) * | 2000-07-19 | 2008-10-07 | Pepgen Corporation | Method of treating IL-10 deficiency |
| DE10053053A1 (de) * | 2000-10-19 | 2002-05-16 | Knoell Hans Forschung Ev | Pharmazeutische Formulierungen zur Hemmung von entzündlichen Arthritiden |
| US20030162732A1 (en) * | 2001-07-05 | 2003-08-28 | Astion Development A/S | Combination of aminosugars and cysteine or cysteine derivatives |
| ITPD20020271A1 (it) * | 2002-10-18 | 2004-04-19 | Fidia Farmaceutici | Composti chimico-farmaceutici costituiti da derivati dei taxani legati covalentemente all'acido ialuronico o ai suoi derivati. |
| DE10349722A1 (de) * | 2003-10-23 | 2005-06-16 | Beschorner, Katharina, Dr. | Zusammensetzung zur Arthrose-/Arthritisbehandlung, insbesondere von Gelenken |
| DE10352137A1 (de) * | 2003-11-04 | 2005-06-16 | Beschorner, Katharina, Dr. | Verwendung sulfatierter Hyaluronsäure |
| ITPD20040245A1 (it) * | 2004-10-08 | 2005-01-08 | Fidia Advanced Biopolymers Srl | Biomateriali costituiti da acido ialuronico solfatato e gellano utilizzabili nella prevenzione delle adesioni spinali |
| DE102005004643B4 (de) * | 2005-01-28 | 2010-04-08 | Innovent E.V. Technologieentwicklung | Antivirale Kombinationen sowie ihre Verwendung |
| ITPD20050168A1 (it) * | 2005-06-01 | 2006-12-02 | Fidia Advanced Biopolymers Srl | Formulazioni di acido lipoico ed acido ialuronico e o suoi derivati e loro impiego in campo farmaceutico e cosmetico |
| US7517856B2 (en) * | 2005-10-11 | 2009-04-14 | Ben-Gurion University Of The Negev Research And Development Authority | Bioconjugates comprising sulfated polysaccharides and their uses |
| JP4220513B2 (ja) * | 2005-12-01 | 2009-02-04 | 株式会社資生堂 | カチオン化ヒアルロン酸 |
| ITPD20060219A1 (it) * | 2006-05-31 | 2007-12-01 | Fidia Farmaceutici | Composizioni farmaceutiche contenenti acido ialuronico solfatato nel trattamento dell'osteoartrosi |
| EP2025687A1 (en) * | 2007-07-23 | 2009-02-18 | Istituto Scientifico di Chimica E Biochimica "G Ronzoni | Process for the preparation of heparanase-inhibiting sulfated hyaluronates and products obtained thereby |
| EP2090308A1 (en) * | 2008-02-15 | 2009-08-19 | Bone Therapeutics | Pharmaceutical composition for the treatment or prevention of osteoarticular diseases |
| IT1397246B1 (it) * | 2009-05-14 | 2013-01-04 | Fidia Farmaceutici | Nuovi medicamenti ad uso topico a base di acido ialuronico solfatato come agente attivante o inibente l'attivita' citochinica |
-
2009
- 2009-05-14 IT ITPD2009A000135A patent/IT1397247B1/it active
-
2010
- 2010-05-11 ES ES16178622T patent/ES2722436T3/es active Active
- 2010-05-11 HR HRP20161575TT patent/HRP20161575T8/hr unknown
- 2010-05-11 LT LTEP10721125.2T patent/LT2429533T/lt unknown
- 2010-05-11 US US13/320,015 patent/US9808482B2/en active Active
- 2010-05-11 EP EP10721125.2A patent/EP2429533B1/en active Active
- 2010-05-11 PL PL10721125T patent/PL2429533T3/pl unknown
- 2010-05-11 WO PCT/EP2010/003044 patent/WO2010130466A1/en not_active Ceased
- 2010-05-11 CN CN201080020643.2A patent/CN102421443B/zh active Active
- 2010-05-11 CA CA2967567A patent/CA2967567C/en active Active
- 2010-05-11 PT PT107211252T patent/PT2429533T/pt unknown
- 2010-05-11 CN CN201810521049.XA patent/CN108379288B/zh active Active
- 2010-05-11 RU RU2011146049/15A patent/RU2552337C2/ru active IP Right Revival
- 2010-05-11 SM SM20190288T patent/SMT201900288T1/it unknown
- 2010-05-11 CA CA2761627A patent/CA2761627C/en active Active
- 2010-05-11 ES ES10721125.2T patent/ES2602498T3/es active Active
- 2010-05-11 HU HUE10721125A patent/HUE031174T2/en unknown
- 2010-05-11 EP EP16178622.3A patent/EP3103459B1/en active Active
- 2010-05-11 SI SI201031341A patent/SI2429533T1/sl unknown
-
2016
- 2016-12-14 SM SM201600456T patent/SMT201600456B/it unknown
-
2017
- 2017-09-20 US US15/710,275 patent/US10548918B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| PL2429533T3 (pl) | 2017-02-28 |
| CN108379288A (zh) | 2018-08-10 |
| US20180008628A1 (en) | 2018-01-11 |
| ITPD20090135A1 (it) | 2010-11-15 |
| CA2761627C (en) | 2017-07-04 |
| SI2429533T1 (sl) | 2017-01-31 |
| US20120101059A1 (en) | 2012-04-26 |
| EP3103459B1 (en) | 2019-02-27 |
| SMT201600456B (it) | 2017-01-10 |
| SMT201900288T1 (it) | 2019-07-11 |
| CA2967567A1 (en) | 2010-11-18 |
| PT2429533T (pt) | 2016-11-14 |
| CA2967567C (en) | 2018-09-11 |
| EP3103459A3 (en) | 2017-01-18 |
| CA2761627A1 (en) | 2010-11-18 |
| IT1397247B1 (it) | 2013-01-04 |
| CN102421443B (zh) | 2018-06-26 |
| WO2010130466A1 (en) | 2010-11-18 |
| CN102421443A (zh) | 2012-04-18 |
| US9808482B2 (en) | 2017-11-07 |
| RU2011146049A (ru) | 2013-06-20 |
| US10548918B2 (en) | 2020-02-04 |
| EP3103459A2 (en) | 2016-12-14 |
| HRP20161575T8 (hr) | 2019-01-25 |
| HUE031174T2 (en) | 2017-06-28 |
| ES2602498T3 (es) | 2017-02-21 |
| EP2429533A1 (en) | 2012-03-21 |
| EP2429533B1 (en) | 2016-09-07 |
| LT2429533T (lt) | 2016-12-12 |
| HRP20161575T1 (hr) | 2016-12-30 |
| HK1258973A1 (zh) | 2019-11-22 |
| CN108379288B (zh) | 2020-10-16 |
| RU2552337C2 (ru) | 2015-06-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112014028095A2 (pt) | sistema de montagem de componente de corpo de veículo, unidade de carro de transporte, sistema de transporte de componente e sistema de transporte de componente com o uso da unidade de carro de transporte | |
| CU20180124A7 (es) | Derivados de aminotiazol útiles como agentes antivíricos | |
| AR085761A1 (es) | Complejos extrudidos a base en almidon para saciedad, reduccion de la absorcion de alimento y manejo de peso | |
| FI4108671T3 (fi) | Muokattuja nukleosideja, nukleotideja ja nukleiinihappoja sekä niiden käyttötapoja | |
| EA201390142A1 (ru) | 2'-фторзамещенные карбануклеозидные аналоги для противовирусного лечения | |
| BR112015002129A2 (pt) | poliésteres | |
| CR11669A (es) | Una patineta | |
| BR112015006429A8 (pt) | sistemas aperfeiçoados de remoção de umidade para sistemas de impressão e estruturas associadas | |
| AR071944A1 (es) | Un articulo absorbente para uso personal alrededor de la cintura del usuario | |
| ES2571583T3 (es) | 6-Sulfato de condroitina biotecnológico de bajo peso molecular para la prevención de la artrosis | |
| CO2019008987A2 (es) | Mejoras en o con respecto a compuestos orgánicos | |
| GT201300021A (es) | Proceso para preparar compuestos antivirales | |
| BR112014027872A2 (pt) | polietilenoimina etoxilada, e, uso de um polímero de polialquilenimina etoxilada solúvel em água | |
| CO7141442A2 (es) | Papel tisú que comprende macroalgas | |
| HRP20161575T1 (hr) | Sulfatirane hijaluronske kiseline kao sredstva za reguliranje aktivnosti citokina | |
| CO2020008993A2 (es) | Sistema ecológico para el aprovechamiento de la energía cinética para vehículos | |
| MX385935B (es) | Formulaciones de derivados de fosforamidato de fármacos de nucleósidos. | |
| BRPI0922701A8 (pt) | Método para intensificar atividade viral mediada por interferon em um animal de companhia | |
| AR066625A1 (es) | Analogos de oligonucleotidos modificados por fosfato con actividad inmunoestimuladora aumentada | |
| PE20131336A1 (es) | Vacunas de virus varicela zoster inactivado, metodos de produccion y uso de las mismas | |
| EA201490963A1 (ru) | Новые производные гемина с антибактериальной и противовирусной активностью | |
| CL2009000798A1 (es) | Uso de un disacárido sulfatado insaturado de sulfato de condroitina definido para preparar una composición útil para desarrollar, proteger y/o reparar tejidos conectivos. | |
| IN2014DN09950A (es) | ||
| TR201908669T4 (tr) | N-desülfatlanmış glikozaminoglikanların türevleri ve ilaç olarak kullanımı. | |
| UY33040A (es) | Nuevas formas polimorfas de {4,6diamino-2-[1-(2-fluorobencil-1h-pirazol[3,4-b]piridin-3-il]pirimidin-5-il}carbamato de metilo |